Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis

Adriana Rojas-Villarraga, Francisco J. Diaz, Enrique Calvo-Páramo, Juan C. Salazar, Antonio Iglesias-Gamarra, Ruben D. Mantilla, Juan Manuel Anaya

Resultado de la investigación: Contribución a RevistaArtículo

48 Citas (Scopus)

Resumen

Rheumatoid arthritis (RA) progresses more rapidly in some patients than in others and diverse factors influence radiographic progression in a specific population. Thus, we searched for variables that are associated with an early appearance of substantial joint damage in patients with RA by using radiographic assessments. A cohort of 157 consecutively enrolled Colombian RA patients was followed for an average of 3.2 ± 3.1 years. Information on patient demographics and cumulative clinical and laboratory manifestations over the course of the disease was registered, including family history of RA in first-degree relatives, extra-articular manifestations, rheumatoid factor, anti-CCP3 antibodies, TNF single nucleotide polymorphism at -308 position, and HLA-DRB1 status. Radiographs were scored according to the Sharp-van der Heijde method. Survival analyses of the time at appearance of substantial joint damage were performed by using Weibull models. A review of literature about the influence of familial RA on the progression of disease was done. Our results show that family history of RA is consistently associated with joint damage (i.e. erosive and joint narrowing disease). This effect was not found in all the populations reviewed. In addition, we confirm the effect of HLA-DRB1 shared epitope and anti-CCP seropositivity on erosive disease. Family history of RA is a key risk factor for joint damage and depends on the investigated population because variations in both additive and non-additive genetic factors and the environmental variance are specific to the population. Our results emphasize the usefulness of assessing familial disease, testing anti-CCP antibodies and genotyping HLA-DRB1 gene in patients with RA because these factors may be used to predict clinical outcomes and guide therapeutic interventions. © 2008 Elsevier Ltd. All rights reserved.
Idioma originalEnglish (US)
Páginas (desde-hasta)64-69
Número de páginas6
PublicaciónJournal of Autoimmunity
DOI
EstadoPublished - feb 1 2009

Huella dactilar

HLA-DRB1 Chains
Epitopes
Anti-Idiotypic Antibodies
Rheumatoid Arthritis
Joints
Population
Joint Diseases
Rheumatoid Factor
Survival Analysis
Single Nucleotide Polymorphism
Disease Progression
Demography

Citar esto

Rojas-Villarraga, Adriana ; Diaz, Francisco J. ; Calvo-Páramo, Enrique ; Salazar, Juan C. ; Iglesias-Gamarra, Antonio ; Mantilla, Ruben D. ; Anaya, Juan Manuel. / Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. En: Journal of Autoimmunity. 2009 ; pp. 64-69.
@article{833cd3daa0ba4c389408c3febe8b5d4e,
title = "Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis",
abstract = "Rheumatoid arthritis (RA) progresses more rapidly in some patients than in others and diverse factors influence radiographic progression in a specific population. Thus, we searched for variables that are associated with an early appearance of substantial joint damage in patients with RA by using radiographic assessments. A cohort of 157 consecutively enrolled Colombian RA patients was followed for an average of 3.2 ± 3.1 years. Information on patient demographics and cumulative clinical and laboratory manifestations over the course of the disease was registered, including family history of RA in first-degree relatives, extra-articular manifestations, rheumatoid factor, anti-CCP3 antibodies, TNF single nucleotide polymorphism at -308 position, and HLA-DRB1 status. Radiographs were scored according to the Sharp-van der Heijde method. Survival analyses of the time at appearance of substantial joint damage were performed by using Weibull models. A review of literature about the influence of familial RA on the progression of disease was done. Our results show that family history of RA is consistently associated with joint damage (i.e. erosive and joint narrowing disease). This effect was not found in all the populations reviewed. In addition, we confirm the effect of HLA-DRB1 shared epitope and anti-CCP seropositivity on erosive disease. Family history of RA is a key risk factor for joint damage and depends on the investigated population because variations in both additive and non-additive genetic factors and the environmental variance are specific to the population. Our results emphasize the usefulness of assessing familial disease, testing anti-CCP antibodies and genotyping HLA-DRB1 gene in patients with RA because these factors may be used to predict clinical outcomes and guide therapeutic interventions. {\circledC} 2008 Elsevier Ltd. All rights reserved.",
author = "Adriana Rojas-Villarraga and Diaz, {Francisco J.} and Enrique Calvo-P{\'a}ramo and Salazar, {Juan C.} and Antonio Iglesias-Gamarra and Mantilla, {Ruben D.} and Anaya, {Juan Manuel}",
year = "2009",
month = "2",
day = "1",
doi = "10.1016/j.jaut.2008.11.004",
language = "English (US)",
pages = "64--69",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",

}

Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. / Rojas-Villarraga, Adriana; Diaz, Francisco J.; Calvo-Páramo, Enrique; Salazar, Juan C.; Iglesias-Gamarra, Antonio; Mantilla, Ruben D.; Anaya, Juan Manuel.

En: Journal of Autoimmunity, 01.02.2009, p. 64-69.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis

AU - Rojas-Villarraga, Adriana

AU - Diaz, Francisco J.

AU - Calvo-Páramo, Enrique

AU - Salazar, Juan C.

AU - Iglesias-Gamarra, Antonio

AU - Mantilla, Ruben D.

AU - Anaya, Juan Manuel

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Rheumatoid arthritis (RA) progresses more rapidly in some patients than in others and diverse factors influence radiographic progression in a specific population. Thus, we searched for variables that are associated with an early appearance of substantial joint damage in patients with RA by using radiographic assessments. A cohort of 157 consecutively enrolled Colombian RA patients was followed for an average of 3.2 ± 3.1 years. Information on patient demographics and cumulative clinical and laboratory manifestations over the course of the disease was registered, including family history of RA in first-degree relatives, extra-articular manifestations, rheumatoid factor, anti-CCP3 antibodies, TNF single nucleotide polymorphism at -308 position, and HLA-DRB1 status. Radiographs were scored according to the Sharp-van der Heijde method. Survival analyses of the time at appearance of substantial joint damage were performed by using Weibull models. A review of literature about the influence of familial RA on the progression of disease was done. Our results show that family history of RA is consistently associated with joint damage (i.e. erosive and joint narrowing disease). This effect was not found in all the populations reviewed. In addition, we confirm the effect of HLA-DRB1 shared epitope and anti-CCP seropositivity on erosive disease. Family history of RA is a key risk factor for joint damage and depends on the investigated population because variations in both additive and non-additive genetic factors and the environmental variance are specific to the population. Our results emphasize the usefulness of assessing familial disease, testing anti-CCP antibodies and genotyping HLA-DRB1 gene in patients with RA because these factors may be used to predict clinical outcomes and guide therapeutic interventions. © 2008 Elsevier Ltd. All rights reserved.

AB - Rheumatoid arthritis (RA) progresses more rapidly in some patients than in others and diverse factors influence radiographic progression in a specific population. Thus, we searched for variables that are associated with an early appearance of substantial joint damage in patients with RA by using radiographic assessments. A cohort of 157 consecutively enrolled Colombian RA patients was followed for an average of 3.2 ± 3.1 years. Information on patient demographics and cumulative clinical and laboratory manifestations over the course of the disease was registered, including family history of RA in first-degree relatives, extra-articular manifestations, rheumatoid factor, anti-CCP3 antibodies, TNF single nucleotide polymorphism at -308 position, and HLA-DRB1 status. Radiographs were scored according to the Sharp-van der Heijde method. Survival analyses of the time at appearance of substantial joint damage were performed by using Weibull models. A review of literature about the influence of familial RA on the progression of disease was done. Our results show that family history of RA is consistently associated with joint damage (i.e. erosive and joint narrowing disease). This effect was not found in all the populations reviewed. In addition, we confirm the effect of HLA-DRB1 shared epitope and anti-CCP seropositivity on erosive disease. Family history of RA is a key risk factor for joint damage and depends on the investigated population because variations in both additive and non-additive genetic factors and the environmental variance are specific to the population. Our results emphasize the usefulness of assessing familial disease, testing anti-CCP antibodies and genotyping HLA-DRB1 gene in patients with RA because these factors may be used to predict clinical outcomes and guide therapeutic interventions. © 2008 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.jaut.2008.11.004

DO - 10.1016/j.jaut.2008.11.004

M3 - Article

SP - 64

EP - 69

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

ER -